Süner A, Aydın D, Hacıoğlu M B, Doğu G G, İmamoğlu G I, Menekşe S, Pilancı K N, Yazıcı Ö K, Koca D, Karaağaç M, Akyol M, Akman T, Ergen S, Avcı N, Kaçan T, Bozkurt O, Kefeli U, Urakçı Z, Araz M, Arpacı E, Harputlu H, Sevinç A
Medical Oncology, Gaziantep University, Gaziantep, Turkey.
Eur Rev Med Pharmacol Sci. 2016 Apr;20(7):1238-43.
Prostate cancer is among the most common cancers in males. Prostate cancer is androgen dependent in the beginning, but as time progresses, it becomes refractory to androgen deprivation treatment. At this stage, docetaxel has been used as standard treatment for years. Cabazitaxel has become the first chemotherapeutic agent which has been shown to increase survival for patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) that progresses after docetaxel. Phase 3 TROPIC study demonstrated that cabazitaxel prolongs survival.
In this study, we evaluated a total of 103 patients who took cabazitaxel chemotherapy for mCRPC diagnosis in 21 centers of Turkey, retrospectively. This study included patients who progressed despite docetaxel treatments, had ECOG performance score between 0-2, and used cabazitaxel treatment. Patients received cabazitaxel 25 mg/m2 at every 3 weeks, and prednisolone 5 mg twice a day.
Median number of cabazitaxel cures was 5.03 (range: 1-17). Cabazitaxel response evaluation detected that 34% of the patients had a partial response, 22.3% had stable disease and 32% had a progressive disease. Grade 3-4 hematological toxicities were neutropenia (28.2%), neutropenic fever (14.5%), anemia (6.7%), and thrombocytopenia (3.8%). In our study, median progression-free survival (PFS) was 7.7 months and overall survival (OS) was 10.6 months.
This study reflects toxicity profile of Turkish patients as a Caucasian race. We suggest that cabazitaxel is a safe and effective treatment option for mCRPC patients who progress after docetaxel. Moreover, ethnicity may play important roles both in treatment response and in toxicity profile.
前列腺癌是男性最常见的癌症之一。前列腺癌起初依赖雄激素，但随着时间推移，它会对雄激素剥夺治疗产生耐药性。在此阶段，多西他赛多年来一直作为标准治疗药物。卡巴他赛已成为首个被证明可提高多西他赛后病情进展的转移性去势抵抗性前列腺癌（mCRPC）患者生存率的化疗药物。3期TROPIC研究表明卡巴他赛可延长生存期。
在本研究中，我们回顾性评估了土耳其21个中心共103例因mCRPC诊断接受卡巴他赛化疗的患者。本研究纳入了尽管接受多西他赛治疗仍病情进展、东部肿瘤协作组（ECOG）体能状态评分为0 - 2且接受卡巴他赛治疗的患者。患者每3周接受25 mg/m²的卡巴他赛治疗，以及每日两次、每次5 mg的泼尼松龙治疗。
卡巴他赛治疗的中位疗程数为5.03（范围：1 - 17）。卡巴他赛疗效评估发现，34%的患者有部分缓解，22.3%病情稳定，32%病情进展。3 - 4级血液学毒性包括中性粒细胞减少（28.2%）、中性粒细胞减少性发热（14.5%）、贫血（6.7%）和血小板减少（3.8%）。在我们的研究中，中位无进展生存期（PFS）为7.7个月，总生存期（OS）为10.6个月。
本研究反映了作为白种人的土耳其患者的毒性特征。我们认为卡巴他赛对于多西他赛后病情进展的mCRPC患者是一种安全有效的治疗选择。此外，种族在治疗反应和毒性特征方面可能都起着重要作用。
